Results 61 to 70 of about 1,571,497 (188)

Old data, new tricks: Comprehensive computational analysis of 10 years of multi‐center EuroFlow acute myeloid leukemia diagnostic immunophenotypic data

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Acute myeloid leukemia (AML) is characterized by high genotypic and immunophenotypic heterogeneity. We collected an extensive dataset containing 5366 flow cytometry files from 885 AML patients, stained with the EuroFlow acute leukemia orientation tube (ALOT) and AML/MDS panel, acquired in a standardized way at eight centers over a period of 10 
Sarah Bonte, Rosan Olsman, Sofie Van Gassen, Sergio Matarraz, Neus Villamor, Stefan Nierkens, Paula Fernandez, Elaine Sobral da Costa, Carmen‐Mariana Aanei, Alberto Orfao, Jacques J. M. van Dongen, Yvan Saeys, Mattias Hofmans, Vincent H. J. van der Velden   +13 more
wiley   +1 more source

Leucemia promielocítica aguda: avaliação retrospectiva dos casos diagnosticados e tratados pelo serviço de hematologia do hospital universitário da Universidade Federal de Santa Catarina entre 2001 a 2013 [PDF]

, 2014
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde, Programa de Pós-Graduação em Farmácia, Florianópolis, 2014.A leucemia promielocítica aguda (LPA) é um subtipo distinto de leucemia mieloide aguda (LMA ...
Durigon, Giovanna Steffenello
core  

PML-RARα co-operates with Sox4 in acute myeloid leukemia development in mice

Haematologica, 2013
Acute promyelocytic leukemia is characterized by a chromosomal translocation involving the retinoic acid receptor alpha gene. To identify co-operating pathways to leukemogenesis, we crossed MRP8-PML/RARA transgenic mice with BXH-2 mice which harbor an ...
Nader Omidvar, Mei Lin Maunakea, Letetia Jones, Sabina Sevcikova, Bin Yin, Karen L. Himmel, Thelma R. Tennant, Michelle M. Le Beau, David A. Largaespada, Scott C. Kogan   +9 more
doaj   +1 more source

Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5‐Year Analysis of the Phase 3 POETYK PSO‐1, PSO‐4, and Long‐Term Extension Trials

The Journal of Dermatology, EarlyView.
ABSTRACT Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of moderate to severe plaque psoriasis, as well as generalized pustular and erythrodermic psoriasis in Japan. Deucravacitinib 6 mg once daily was efficacious and well tolerated through 3 years in the pooled population of ...
Yukari Okubo, Akimichi Morita, Yayoi Tada, Shinichi Imafuku, April W. Armstrong, Andrew Blauvelt, John Vaile, Zoran Popmihajlov, Janice Li, Rajesh Sawant, Katsuyoshi Habiro, Katsuki Tsuritani, Mamitaro Ohtsuki   +12 more
wiley   +1 more source

Molecular and hematologic relapses in adult patients with acute promyelocytic leukemia: a cohort study

Revista Brasileira de Hematologia e Hemoterapia
Objective: To evaluate factors predictive for relapse in a cohort of adult patients with acute promyelocytic leukemia monitored by molecular methods during consolidation and during at least one month of maintenance therapy.
Ilana de França Azevedo, Michelline Gomes Magalhães, Fernanda Ribeiro Souto, Washington Batista das Neves, Fárida Coeli de Barros Correia Melo, Eduardo Magalhães Rego, Raul Antônio Morais Melo   +6 more
doaj   +1 more source

ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia

Haematologica, 2019
Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia. However, excluding acute promyelocytic leukemia, clinical benefits of differentiation therapies are negligible in acute myeloid ...
Jianbiao Zhou, Jessie Yiying Quah, Yvonne Ng, Jing-Yuan Chooi, Sabrina Hui-Min Toh, Baohong Lin, Tuan Zea Tan, Hiroki Hosoi, Motomi Osato, Qihui Seet, A.G. Lisa Ooi, Bertil Lindmark, Mark McHale, Wee-Joo Chng   +13 more
doaj   +1 more source

Proteomics of Acute Myeloid Leukemia [PDF]

, 2007
Acute Myeloid Leukemia (AML) is characterized by specific cytogenetic aberrations that are strong determinants of prognostic outcome and therapeutic response.
Yaseen, Mumtaz
core   +1 more source

Acute promyelocytic leukemia presenting as an extradural mass

Revista Brasileira de Hematologia e Hemoterapia, 2011
Acute promyelocytic leukemia is potentially a highly curable type of leukemia that usually presents with pancytopenia, coagulopathies and bleeding. We describe a case of an unusual presentation of acute promyelocytic leukemia.
Henrique Bittencourt, Antonio Lucio Teixeira Junior, Ana Beatriz Firmato Glória, Ana Flávia Leonardi Tiburcio Ribeiro, Evandro Maranhão Fagundes   +4 more
doaj   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors [PDF]

, 2002
FLT3 mutations, either internal tandem duplications (ITDs) or aspartate residue 835 (D835) point mutations, are present in approximately one third of patients with acute myeloid leukemia (AML) and have been associated with an increased relapse rate.
Kottaridis, P.D., Gale, R.E., Bowen, D.T., Langabeer, S.E., Frew, M.E., Linch, D.C.   +5 more
core